



WORLD **DIABETES** FOUNDATION

MEDIA BACKGROUNDER

World Diabetes Foundation, members of the board

Lottenborgvej 24
DK-2800 Kgs. Lyngby
Denmark

Phone +45 44 43 17 09
Fax +45 44 44 47 52

jmbu@worlddiabetesfoundation.org
www.worlddiabetesfoundation.org

Professor Pierre Lefèbvre

Chairman, World Diabetes Foundation

Professor Lefèbvre received his MD Degree and PhD at the University of Liège in 1959 and 1967, respectively. Professor Lefèbvre is presently Emeritus Professor of Medicine at the University of Liège and Consultant at the Liège University Hospital. He is the former President of the International Diabetes Federation (IDF).

Professor Lefèbvres research has been devoted to the physiology and pathophysiology of metabolic regulations with particular emphasis on glucagon, insulin and physical exercise. He has published more than 25 books and 900 papers. Pierre Lefèbvre has performed numerous studies on the pathology and treatment of non-insulin-dependent diabetes and obesity and he serves or has served on the Editorial Board of more than twenty International Journals.

Professor Lefèbvre has been President of the Belgian Diabetes Association and the European Association for the Study of Diabetes.

Mr Leif Fenger Jensen

Vice Chairman, World Diabetes Foundation

Mr Leif Fenger Jensen has been with WDF since its establishment and inauguration early 2002 as the Managing Director. Before joining WDF, Mr Jensen worked at Novo Nordisk for more than 10 years where he held several managerial positions. Between 1996 and 2001 Mr. Jensen worked as Regional Finance & HR Director in the Asia Pacific Centre located in Singapore. Mr Jensen has presently been appointed as Vice President of Strategic Operations at the Novo Nordisk Office in Zürich.

Professor Ib Bygbjerg

Professor Bygbjerg is a Professor in the Department of International Health at The Panum Institute, Denmark. As a specialist in tropical medicine and infectious diseases, Professor Bygbjerg has shared his expertise with organisations including the Danish Ministry of Defence, the World Health Organisation and the Danish Ministry of Foreign Affairs. Professor Bygbjerg is also a member of DANIDA's Research Council and of numerous professional bodies, including the World Federation for Medical Education, the International Board of the Danish Red Cross and the American Society of Tropical Medicine and Hygiene. His involvement in such organisations has prompted extensive travel within the developing world and he has spent significant lengths of time in India, Tanzania and the Democratic Republic of Congo.



Ida Nicolaisen

Ms Nicolaisen is a Senior Research Fellow at the Nordic Institute of Asian Studies at Copenhagen University. Before taking up her current position Ms Nicolaisen held a position as Associate Professor also at Copenhagen University. Ms Nicolaisen is specialized in cultural anthropology and socio-economic development and holds a great expertise of the challenges of the third world countries through her job and membership of several boards such as the Permanent Forum of Indigenous Issues (UN), DANIDA, Foundation of His Royal Highness Crown Prince Frederik and International Human Rights. Furthermore, Ms Nicolaisen is consulting DANIDA, UNSO, Sarawak museum and WWF in different matters.

Lars Rebién Sørensen

Mr Sørensen is president and CEO of the pharmaceutical company Novo Nordisk, known for its' social responsibility and dedication to improve life for people with diabetes. Through this position Lars Rebién Sørensen is one of the founding fathers of WDF. Mr Sørensen has spent most of his career in Novo Nordisk. First in Novo Nordisk's Enzymes Marketing department and later on as president of International Operations of the Bioindustrial Group before joining the Corporate Management and later on appointed president and CEO in 2000. Mr Sørensen has a Master's degree in forestry from the Royal Danish Veterinary and Agricultural University and a BSc in International Economics from The Copenhagen Business School in 1983.

Mr Sørensen is also a member of the Board of Scandinavian Airlines System AB and ZymoGenetics Inc.

Dr Kaushik Ramaiya

Dr. Ramaiya is Consultant Physician and Assistant Medical Administrator at Shree Hindu Mandal Hospital, Dar es Salaam, Tanzania.

Dr. Ramaiya also holds several other honorary appointments such as Chairman, International Diabetes Federation Africa Region, Hon. General Secretary of Tanzania Diabetes Association and member of the Board of National Health Insurance Fund, Ministry of Health, Govt. of United Republic of Tanzania. He has produced numerous publications on diabetes research and has implemented many initiatives and studies to put diabetes on the health agenda in Africa.

Dr Ramaiya has been the catalyst force and project responsible behind many WDF funded projects in Tanzania.



For further information please contact

Jamal Butt

Communication Manager

Phone direct: +45 44 43 47 36

Mobile: + 45 30 75 47 36

Email: JmBu@worlddiabetesfoundation.org

The World Diabetes Foundation

World Diabetes Foundation is dedicated to supporting prevention and treatment of diabetes in the developing world through funding of sustainable projects. The World Diabetes Foundation creates partnerships and acts as a catalyst to help others do more. The Foundation strives to educate and advocate globally in an effort to create awareness, care and relief to those impacted by diabetes. The World Diabetes Foundation has funded 208 projects to date in 87 countries with a total portfolio of USD 210.9 million of which USD 70.6 million are donated by the Foundation. The projects funded by the WDF will in the coming 3-4 years potentially influence the diabetes treatment, prevention and awareness efforts of 71.5 million people directly in the developing countries.

The establishment of the World Diabetes Foundation was announced by its founding father Novo Nordisk A/S on World Diabetes Day 2002. A donation programme by the founding company of a maximum of DKK 650 million over a period of ten years was approved by its General Assembly and shareholders in March 2002.

In March 2008, the shareholders of Novo Nordisk A/S approved of an additional endowment of a maximum of DKK 575 million over another ten year-period, bringing the two endowments from Novo Nordisk A/S up to a total maximum of DKK 1.2 billion in the period 2001 - 2017, i.e. equivalent to USD 255 million (exch. rate 4.8). The Foundation is registered as an independent trust and governed by a board of six experts in the field of diabetes, access to health, and development assistance.

For further information please visit our website: www.worlddiabetesfoundation.org